Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs
- PMID: 32099075
- PMCID: PMC8245563
- DOI: 10.1038/s41423-020-0379-x
Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs
Abstract
Activated phosphoinositide 3-kinase δ syndrome (APDS) is an autosomal-dominant combined immunodeficiency disorder resulting from pathogenic gain-of-function (GOF) mutations in the PIK3CD gene. Patients with APDS display abnormal T cell homeostasis. However, the mechanisms by which PIK3CD GOF contributes to this feature remain unknown. Here, with a cohort of children with PIK3CD GOF mutations from multiple regions of China and a corresponding CRISPR/Cas9 gene-edited mouse model, we reported that hyperactive PI3Kδ disrupted TNaive cell homeostasis in the periphery by intrinsically promoting the growth, proliferation, and activation of TNaive cells. Our results showed that PIK3CD GOF resulted in loss of the quiescence-associated gene expression profile in naive T cells and promoted naive T cells to overgrow, hyperproliferate and acquire an activated functional status. Naive PIK3CD GOF T cells exhibited an enhanced glycolytic capacity and reduced mitochondrial respiration in the resting or activated state. Blocking glycolysis abrogated the abnormal splenic T cell pool and reversed the overactivated phenotype induced by PIK3CD GOF in vivo and in vitro. These results suggest that enhanced aerobic glycolysis is required for PIK3CD GOF-induced overactivation of naive T cells and provide a potential therapeutic approach for targeting glycolysis to treat patients with APDS as well as other immune disorders.
Keywords: Activated phosphoinositide3-kinase δ syndrome; Aerobic glycolysis; Naive T cells; PIK3CD; Primary immunodeficiency disorders.
Conflict of interest statement
The authors declare no competing interests.
Figures







Similar articles
-
Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.Front Immunol. 2018 Feb 27;9:369. doi: 10.3389/fimmu.2018.00369. eCollection 2018. Front Immunol. 2018. PMID: 29535736 Free PMC article. Review.
-
Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.J Allergy Clin Immunol. 2019 Jan;143(1):276-291.e6. doi: 10.1016/j.jaci.2018.04.030. Epub 2018 May 22. J Allergy Clin Immunol. 2019. PMID: 29800648
-
Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.Clin Immunol. 2018 Dec;197:60-67. doi: 10.1016/j.clim.2018.08.007. Epub 2018 Aug 20. Clin Immunol. 2018. PMID: 30138677
-
Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells.J Allergy Clin Immunol. 2019 Jul;144(1):236-253. doi: 10.1016/j.jaci.2019.01.033. Epub 2019 Feb 6. J Allergy Clin Immunol. 2019. PMID: 30738173 Free PMC article.
-
Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.Front Pediatr. 2021 Aug 5;9:702872. doi: 10.3389/fped.2021.702872. eCollection 2021. Front Pediatr. 2021. PMID: 34422726 Free PMC article. Review.
Cited by
-
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.J Exp Med. 2023 Jun 5;220(6):e20221020. doi: 10.1084/jem.20221020. Epub 2023 Mar 21. J Exp Med. 2023. PMID: 36943234 Free PMC article.
-
Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib.Cancers (Basel). 2021 Oct 9;13(20):5039. doi: 10.3390/cancers13205039. Cancers (Basel). 2021. PMID: 34680188 Free PMC article.
-
Activated PI3Kδ specifically perturbs mouse Treg homeostasis and function leading to immune dysregulation.bioRxiv [Preprint]. 2023 Dec 23:2023.12.21.569665. doi: 10.1101/2023.12.21.569665. bioRxiv. 2023. Update in: J Immunol. 2024 Jul 15;213(2):135-147. doi: 10.4049/jimmunol.2400032. PMID: 38187650 Free PMC article. Updated. Preprint.
-
Effects of altered glycolysis levels on CD8+ T cell activation and function.Cell Death Dis. 2023 Jul 8;14(7):407. doi: 10.1038/s41419-023-05937-3. Cell Death Dis. 2023. PMID: 37422501 Free PMC article. Review.
-
A guide to interrogating immunometabolism.Nat Rev Immunol. 2021 Oct;21(10):637-652. doi: 10.1038/s41577-021-00529-8. Epub 2021 Apr 15. Nat Rev Immunol. 2021. PMID: 33859379 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous